 |
| |
| |
| |
| |
| |
| |
|
| TissGeneSummary for ASB17 |
 Gene summary |
| Basic gene information | Gene symbol | ASB17 |
| Gene name | ankyrin repeat and SOCS box containing 17 | |
| Synonyms | Asb-17 | |
| Cytomap | UCSC genome browser: 1p31.1 | |
| Type of gene | protein-coding | |
| RefGenes | NM_080868.2, NR_026546.1, | |
| Description | ankyrin repeat and SOCS box protein 17ankyrin repeat and SOCS box-containing 17 | |
| Modification date | 20141207 | |
| dbXrefs | HGNC : HGNC | |
| Ensembl : ENSG00000154007 | ||
| HPRD : 10671 | ||
| Vega : OTTHUMG00000009787 | ||
| Protein | UniProt: go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_ASB17 | |
| BioGPS: 127247 | ||
| Pathway | NCI Pathway Interaction Database: ASB17 | |
| KEGG: ASB17 | ||
| REACTOME: ASB17 | ||
| Pathway Commons: ASB17 | ||
| Context | iHOP: ASB17 | |
| ligand binding site mutation search in PubMed: ASB17 | ||
| UCL Cancer Institute: ASB17 | ||
| Assigned class in TissGDB* | C | |
| Included tissue-specific gene expression resources | HPA,GTEx | |
| Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | Testis | |
| Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | TGCT | |
| Reference showing the relevant tissue of ASB17 | ||
| Description by TissGene annotations | ||
| * Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO term | PubMed ID |
| Top |
| TissGeneExp for ASB17 |
| Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
 |
| Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
 |
| Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| - Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
| Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
| Top |
| TissGene-miRNA for ASB17 |
| Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
| Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
| Top |
| TissGeneMut for ASB17 |
| TissGeneSNV for ASB17 |
| nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
 |
 |
| Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
 |
| - nsSNVs sorted by frequency. |
| AAchange | Cancer type | # samples |
| p.I181T | LUAD | 1 |
| p.I185V | BLCA | 1 |
| p.I26N | STAD | 1 |
| p.P45Q | LUAD | 1 |
| p.I181L | LUSC | 1 |
| p.T5N | LUAD | 1 |
| p.K53T | SKCM | 1 |
| p.V74M | STAD | 1 |
| p.C141S | UCEC | 1 |
| p.P189S | SKCM | 1 |
| p.R80H | LGG | 1 |
| p.D69Y | UCEC | 1 |
| p.R80C | CESC | 1 |
| p.H258P | LUSC | 1 |
| p.L114F | ESCA | 1 |
| p.G78R | SKCM | 1 |
| p.Y57H | LUSC | 1 |
| p.P138S | LGG | 1 |
| p.L115F | LUSC | 1 |
| p.E44K | SKCM | 1 |
| p.S280L | SKCM | 1 |
| p.S126R | LUAD | 1 |
| p.D59N | SKCM | 1 |
| p.V192I | ESCA | 1 |
| p.E294Q | LUAD | 1 |
| p.Y70H | BLCA | 1 |
| p.V154L | UCEC | 1 |
| p.N292T | UCEC | 1 |
| p.T270N | LUAD | 1 |
| p.I185T | LGG | 1 |
| p.G36S | DLBC | 1 |
| p.Y250C | LUAD | 1 |
| p.P246L | SKCM | 1 |
| p.S231I | SKCM | 1 |
| p.E44* | HNSC | 1 |
| p.L51Q | LIHC | 1 |
| p.C42G | ACC | 1 |
| p.T184R | LUAD | 1 |
| p.D88Y | LIHC | 1 |
| p.Y79C | BLCA | 1 |
| p.K53N | LUAD | 1 |
| p.N180K | LUSC | 1 |
| p.S280L | LUSC | 1 |
| p.L282I | ESCA | 1 |
| p.V122A | LUAD | 1 |
| p.D124N | SKCM | 1 |
| p.E44Q | LUAD | 1 |
| p.S77T | LUAD | 1 |
| p.G62S | SKCM | 1 |
| p.A65T | PRAD | 1 |
| p.K6N | OV | 1 |
| p.R29K | BRCA | 1 |
| p.D64N | BRCA | 1 |
| Top |
| TissGeneCNV for ASB17 |
| Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
 |
| Top |
| TissGeneFusions for ASB17 |
| Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
| Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
| Top |
| TissGeneNet for ASB17 |
| Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
| Top |
| TissGeneProg for ASB17 |
| Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
 |
| Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Top |
| TissGeneClin for ASB17 |
| TissGeneDrug for ASB17 |
| Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
| DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Top |
| TissGeneDisease for ASB17 |
| Disease information associated with TissGene (DisGeNet, 2016-06-01) |
| Disease ID | Disease name | # pubmeds | Source |
| umls:C0003944 | As If Personality | 1 | GAD |
Copyright 2016-Present - The University of Texas Health Science Center at Houston (UTHealth) Web File Viewing | How to Report, Fraud, Waste and Abuse | State of Texas | Statewide Search | Texas Homeland Security | Site Policies |